PCC SE intends to consolidate its business activities in the Chlorine & Derivatives segment to further expand vertical integration in this core business area of PCC Group and strengthen it in the long term. The plan is to integrate production and marketing of monochloroacetic acid (MCAA) into PCC Rokita SA, the largest company in the PCC Group and a major chlorine producer. To this end, PCC SE intends to transfer its subsidiaries MCAA SE and PCC MCAA Sp. z o.o. to PCC Rokita SA. PCC SE and PCC Rokita SA signed a letter of intent on June 16, 2026.
The planned transaction is to be carried out through a share swap. The number of new shares to be issued by PCC Rokita SA will be determined on the transaction date based on the six-month weighted average price of the PCC Rokita share (PLPCCRK00076) on the Warsaw Stock Exchange (GPW). If the transaction had taken place on June 5, the weighted six-month average price would have been 68.05 PLN. Based on an independent valuation prepared by PwC Advisory Sp. z o.o. in Poland, the market value of 100% of the shares amounts to the equivalent of approximately €68 million. Based on this, 4,251,619 new shares of PCC Rokita SA would be issued to PCC SE.
PCC Rokita SA operates the PCC Group’s major production site in Brzeg Dolny, Poland, where it produces, among other things, chlorine. This base chemical is input for monochloroacetic acid (MCAA), which is produced and marketed at the same site by PCC MCAA Sp. z o.o. The planned transfer to PCC Rokita SA will consolidate the business activities in this core business area and they will be managed centrally in the future. With this integration, PCC Group intends to achieve further process optimizations with significant synergy effects for the business units and, consequently, for the entire Group.
The decision to proceed with the potential transaction described in this non-binding letter of intent is subject to various standard market conditions. In particular, this applies to the necessary corporate approvals from both companies.
